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Abstract
Background:  A novel fluorescent cAMP analog (8-[Pharos-575]- adenosine-3', 5'-cyclic
monophosphate) was characterized with respect to its spectral properties, its ability to bind to and
activate three main isoenzymes of the cAMP-dependent protein kinase (PKA-Iα, PKA-IIα, PKA-IIβ)
in vitro, its stability towards phosphodiesterase and its ability to permeate into cultured eukaryotic
cells using resonance energy transfer based indicators, and conventional fluorescence imaging.
Results: The Pharos fluorophore is characterized by a Stokes shift of 42 nm with an absorption
maximum at 575 nm and the emission peaking at 617 nm. The quantum yield is 30%. Incubation of
the compound to RIIα and RIIβ subunits increases the amplitude of excitation and absorption
maxima significantly; no major change was observed with RIα. In vitro binding of the compound to
RIα subunit and activation of the PKA-Iα holoenzyme was essentially equivalent to cAMP; RII
subunits bound the fluorescent analog up to ten times less efficiently, resulting in about two times
reduced apparent activation constants of the holoenzymes compared to cAMP. The cellular uptake
of the fluorescent analog was investigated by cAMP indicators. It was estimated that about 7 μM of
the fluorescent cAMP analog is available to the indicator after one hour of incubation and that about
600 μM of the compound had to be added to intact cells to half-maximally dissociate a PKA type
IIα sensor.
Conclusion: The novel analog combines good membrane permeability- comparable to 8-Br-cAMP
– with superior spectral properties of a modern, red-shifted fluorophore. GFP-tagged regulatory
subunits of PKA and the analog co-localized. Furthermore, it is a potent, PDE-resistant activator of
PKA-I and -II, suitable for in vitro applications and spatial distribution evaluations in living cells.
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Background
Fluorescent nucleotides have become widely utilized
tools in basic research [1], and the number of correspond-
ing reports on their use in cellular systems is vast. How-
ever studies involving the second messenger cAMP have
not kept pace, and studies using fluorescently tagged
cAMP analogs are still limited.
Early reports mainly used nucleobase-modified analogs
where the purine ring system was part of the fluorophore,
such as 1, N6- etheno-cAMP [2], 2- aza- 1, N6- etheno-
cAMP [3] or the cyclic phosphate of 2- aminopurine ribo-
side [4]. However, these compounds are far from being
optimal with regard to membrane permeability, cAMP-
dependent protein kinase (PKA) binding affinity and sta-
bility towards phosphodiesterases (PDEs). Further more,
the fluorophores lack brilliance and possess unfavorable
spectral properties, e.g., excitation is to be performed in
the UV range, which can be harmful to intact cells and
monitoring of the relatively short emission wavelengths is
often disturbed by intrinsic fluorescent components of
the cell.
For studies involving PDEs, anthraniloyl [5]- and methyl-
anthraniloyl- modified [6] cAMP (MANT-cAMP) have
been introduced, where the ribose 2- position carries a flu-
orescent reporter group. Since the 2'- modification render
these structures unable to activate PKA, the MANT group
has been linked to the positions 6 [7] and 8 [8] of the ade-
nine nucleobase as well (MABA-cAMP). According to cor-
responding lipophilicity data (log kw), cyclic nucleotides
with MANT modification have improved membrane per-
meability and better PDE-resistance (at least 6- and 8-
modified structures), but are still suboptimal with respect
to their spectral properties. The same holds true for cAMP
modified with the NBD fluorophore (8-[2-[(7-Nitro-4-
benzofurazanyl)amino]ethyl]thio]adenosine-3',5'-cyclic
monophosphate; 8-NBD-cAMP) [6].
Fluorescein and rhodamine have been attached to the 8-
position of cAMP as well [9], however, in spite of the
improved spectral properties of these dyes, both conju-
gates are not membrane permeable due to an additional
charge within the dye moiety. Unfortunately, nearly all
modern fluorescent dye structures contain positive or neg-
ative charges which support the electronic push/pull
mechanism of the respective chromophore but render the
corresponding conjugates rather polar, especially when
attached to nucleotides with their polar phosphate
groups. Even cAMP conjugates with state-of-the-art dyes
such as Cy3 [10], Evoblue, and Bodipy® [11,12], which
have excellent spectral properties, fail to pass cellular
membranes, and require invasive application techniques
like patch clamp or microinjection or the osmotic lysis of
pinocytic vesicles [13] and are mainly utilized in vitro
assays. Importantly, if these dyes are connected to the 2'-
ribose moiety, the resulting conjugates will not bind to
and activate PKA anymore. Finally, phosphate-modified
caged cAMP analogs have been described, which – upon
photo-activation – release cAMP together with fluorescent
coumarines [14,15].
Thus, in spite of quite a number of different fluorescent
variants of cAMP, these structures have only limited appli-
cation scopes, and presently no analog is available that
offers improved properties in all important aspects men-
tioned, and which could be used with intact cells for track-
ing or intracellular imaging experiments.
The main effector enzyme of cAMP is the cAMP-depend-
ent protein kinase (PKA), which reversibly phosphor-
ylates substrate proteins. Protein kinases and their counter
players, phosphatases and cAMP-degrading PDEs, are key
regulatory enzymes in eukaryotic cells. PKA is a multi-sub-
strate enzyme mediating the majority of the known effects
of cAMP by regulating the activity of proteins involved in
signal transduction, energy metabolism, cell proliferation,
and differentiation [16]. In the absence of cAMP, all PKA
isoforms consist of two regulatory (R) and two catalytic
subunits (C) that form an inactive tetramer. Binding of at
total of four cAMP molecules to the two tandem cAMP
binding sites of each R subunit promotes the dissociation
of the holoenzyme complex and leads to the release of the
now active C subunits phosphorylating target proteins in
the cytosol or in the nucleus [17]. Main isoforms of the C
subunit are Cα, Cβ, Cγ and PrKX, and several minor iso-
forms have been identified at least at cDNA level. In
human, four different isoforms of the R subunit (RIα, RIβ,
RIIα, RIIβ) have been identified [18].
Besides PKA and its corresponding signaling pathway,
cAMP addresses additional cellular targets such as cyclic
nucleotide-dependent ion channels (cyclic nucleotide
gated ion channel and hyperpolarization-activated cyclic
nucleotide-modulated channel) as well as the exchange
protein directly activated by cAMP (Epac), which are
worthwhile objects for evaluation with fluorescent ana-
logs [19,20].
In view of the importance of the cAMP messenger system,
improved tools for a more detailed investigation of func-
tions and receptor distribution would be quite helpful.
Thus, in this study, the properties of a novel commercially
available conjugate of cAMP with the Pharos dye, 8-[Pha-
ros-575]- adenosine-3', 5'-cyclic monophosphate (8-[ϕ-
575]-cAMP) and the corresponding free dye were investi-
gated and analyzed physico-chemically (spectral proper-
ties, stability), with respect to PKA-RI and -RII subunit
binding as well as holoenzyme activation in vitro and in
living cells, PDE-resistance, and cellular uptake.BMC Biochemistry 2008, 9:18 http://www.biomedcentral.com/1471-2091/9/18
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Results and Discussion
Photochemical characterization of the Pharos dye
First we determined the photo-chemical properties of the
free Pharos dye. The Stokes shift at pH 6.0, pH 7.0 and pH
7.4 was 42 nm resulting from an absorption maximum at
575 nm and an emission maximum at 617 nm (Fig. 1;
ε575nm = 15,650). 8-[ϕ-575]-cAMP behaved similarly with
an excitation maximum at 577 nm and emission maxi-
mum at 605 nm at pH 7.0 (Fig. 2, and data not shown).
To calculate the relative quantum yield ϕ of the Pharos
dye the absorption (500 nm to 640 nm) and fluorescence
(λex = 553 nm, λem ranging from 558 nm to 800 nm) spec-
tra of several Pharos dye concentrations (640 nM to 64.2
μM) were recorded using quinine sulfate as a standard
[21,22]. The determination of the relative quantum yield
is generally accomplished by plotting the integrated fluo-
rescence intensity versus the absorbance at the excitation
wavelength (see Additional file 1, panel a). By comparing
the slope of the linear regression (see Additional file 1,
panel b) with that of a standard substance (quinine sul-
fate), the relative quantum yield of the Pharos dye was
determined to be 30%.
Spectral properties of 8-[ϕ-575]-cAMP upon binding to 
PKA R-subunits
8-[ϕ-575]-cAMP was incubated with or without a fourfold
molar excess of RIα, RIIα and RIIβ subunits (Fig. 2). The
excitation spectra (a) were detected at Em 617 nm and Ex
610 nm-430 nm; the emission spectra (b) were detected at
Ex 575 nm and Em 680 nm – 580 nm. Upon addition of
RIIα and RIIβ subunits we observed an increase of the
amplitude of excitation and emission maxima, whereas
the interaction of the analog with RIα protein had no sig-
nificant effect. Furthermore, a slight shift of the excitation
and emission spectra to shorter wavelengths (Ex = 570
nm; Em = 600 nm) was found with all three R subunits.
8-[ϕ-575]-cAMP binding to PKA R subunits and activation 
of PKA
It has been shown that cAMP analogs, modified in posi-
tion 8 of the adenine nucleobase, are powerful activators
of protein kinase A, and even rather bulky substituents are
accepted here. In addition, all analogs modified with
fluorophores of high molecular weight and steric
demands were reported to be potent PKA agonists[7].
Fluorescence spectra of 8-[ϕ-575]-cAMP bound to PKA R  subunits Figure 2
Fluorescence spectra of 8-[ϕ-575]-cAMP bound to 
PKA R subunits. 150 nM 8-[ϕ-575]-cAMP was incubated 
with or without fourfold molar excess of PKA R subunits as 
indicated in the figure. The excitation spectra (a) were 
detected at Em 617 nm and Ex 610 nm-430 nm; the emission 
spectra (b) were detected at Ex 575 nm and Em 680 nm-580 
nm. The experiments were repeated four times with similar 
results.
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Fluorescence absorption and emission spectra of the Pharos  dye Figure 1
Fluorescence absorption and emission spectra of the 
Pharos dye. The absorption maxima of the Pharos dye dis-
solved in buffer with the indicated pH values is at 575 nm, 
whereas the emission maxima are at 617 nm. All spectra 
exhibit a large Stokes shift of 42 nm.
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To investigate the binding of 8-[ϕ-575]-cAMP to RI and
RII subunits, we employed a fluorescent polarization dis-
placement assay using 2.5 nM R subunit. Displacement of
8-Fluo-cAMP bound to the R subunits was followed by
allowing either cAMP or 8-[ϕ-575]-cAMP to compete with
8-Fluo-cAMP binding. In the case of RIα, we found 8-[ϕ-
575]-cAMP and cAMP bound equally well to the R subu-
nit (Fig. 3a). In case of RIIα and RIIβ, cAMP was about 10
times and 5 times more efficient in displacing 8-Fluo-
cAMP compared to 8-[ϕ-575]-cAMP, respectively (Fig. 3b
und 3c). With respect to both, isoform and site selectivity,
and considering the bulky substituent in position 8 of the
adenine nucleobase, it could have been expected that 8-
[ϕ-575]-cAMP prefers the B- site of PKA type II. However,
our data show that binding to RIα is comparable to cAMP,
whereas a lower affinity of 8-[ϕ-575]-cAMP for RII iso-
forms was detected. In this respect, 8-[ϕ-575]-cAMP acts
similar to 8-Fluo-cAMP, which shows rather high affinity
for the site BII along with rather lower affinity to AII, but
a quite equal binding capacity to both sites A and B of RI,
thus resulting in an overall higher binding to RIα [23],
analogous to other 8-substituted analogs [24,25].
We next investigated the ability of 8-[ϕ-575]-cAMP to acti-
vate PKA-I and -II holoenzymes side by side. RIα, RIIα and
RIIβ each were allowed to form a holoenzyme complex
with the Cα subunit, before adding increasing amounts of
either cAMP or 8-[ϕ-575]-cAMP to re-activate the Cα-sub-
unit. Kinase activity was assayed spectrophotometrically
[26], using the synthetic heptapeptide Kemptide as a sub-
strate. The binding properties of 8-[ϕ-575]-cAMP to the
RIα subunit is reflected in a nearly identical activation
titration curve and corresponding activation constant
comparing analog (EC50 = 150 nM) with cAMP (EC50 =
120 nM, [27,28], Fig. 4a). However, activation of RIIα and
RIIβ holoenzymes was less cooperative using 8-[ϕ-575]-
cAMP, indicated by a more shallow hill slope of the acti-
vation titration curves (Fig. 4a and 4b). The correspond-
ing apparent activation constants (EC50-values) were
about two-fold increased for 8-[ϕ-575]-cAMP compared
to cAMP (EC50 RIIα = 280 nM; EC50 RIIβ = 900 nM).
Uptake of 8-[ϕ-575]-cAMP in living cells and activation of 
PKA
Insights into the intracellular distribution within eukary-
otic cells were obtained by intracellular imaging of the
cyclic nucleotide analog. 8-[ϕ-575]-cAMP clearly enters
the cultivated HEK293 and CHO cells. In most cases it dis-
plays a spotty distribution inside the cells and seems to
accumulate in bright aggregates over a diffusely labeled
background. The nuclear compartment was unlabeled in
most cells (Fig. 5a and 5b). In some experiments, employ-
ing COS-7 cells less than 5% of the cells showed an accu-
mulation of the compound in the nucleus, which might
be attributable to apoptotic degeneration of the cells (data
not shown). Variations in the incubation procedure (e.g.
decrease in temperature, addition of pluronic® or serum
during incubation [29,30]) did not significantly change
the distribution pattern or the accumulation in bright
spots. However, an incubation temperature of 4°C led to
a markedly reduced uptake and accumulation of the com-
pound (data not shown). This could indicate that mem-
brane trafficking, which is inhibited at 4°C, is part of the
accumulation process. Whether pinocytotic uptake of the
compound or exocytotic processes involving cAMP are
inhibited [31], deserves further study. The free Pharos dye
efficiently diffuses within the cells and does not accumu-
late in spots like 8-[ϕ-575]-cAMP does (Fig. 5c and 5d).
It has previously been shown that fluorescent cAMP ana-
logs were able to label RIα aggregates, respectively [32-
34]. We therefore investigated whether the compound co-
localizes with GFP-tagged RIα and RIIα proteins expressed
in COS-7 cells, and indeed we found co-localization of 8-
[ϕ-575]-cAMP, but not the free dye, with R subunits (Fig.
6, and data not shown), indicating that the accumulation
of the fluorescent cAMP might be in part due to associa-
tion to (clustered) cAMP binding proteins. However, we
can not entirely exclude unspecific aggregation of 8-[ϕ-
575]-cAMP.
In contrast to many other modern fluorophores, the Pha-
ros chromophore has considerably reduced bulkiness
along with high lipophilicity. Thus, 8-[ϕ-575]-cAMP has a
lower molecular weight compared to e.g. fluorescein-
modified-cAMP (8-[2-[(Fluoresceinylthioureido)
amino]ethyl]thio]adenosine-3', 5'-cyclic monophos-
phate; 8-Fluo-cAMP). Due to its merely hydrophobic
character, the dye has a big impact on the analog overall
lipophilicity, which in turn should compensate the nega-
tive charge of the cyclic phosphate and finally lead to
good membrane permeability of 8-[ϕ-575]-cAMP. In
lipophilicity measurements using reversed phase HPLC
[35], its logKw was determined to be 2.95 resulting in a
more than 70 times increased lipophilicity compared to
cAMP (data not shown). In this respect the analog resem-
bles highly membrane-permeant PKA agonists such as Sp-
5,6-DCl-cBIMPS [36] or the Epac activator 8-pCPT-2'-O-
Me-cAMP [37], and surpasses all fluorescent cAMP ana-
logs described so far. We therefore investigated the kinet-
ics of 8-[ϕ-575]-cAMP uptake in living cells using a
genetically encoded fluorescent indicator (H30) formed
by a cAMP binding domain from Epac and two spectral
variants of the green fluorescent protein (GFP) [38]. Its
functioning is based on the phenomenon of fluorescence
resonance energy transfer (FRET). FRET relies on a non-
radiative, distance-dependent transfer of energy between
the two fluorescent domains: by exciting the first, the
emission from the second one can be detected. Since FRET
depends on the distance between the two fluorophores BMC Biochemistry 2008, 9:18 http://www.biomedcentral.com/1471-2091/9/18
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Competitive nucleotide binding assay using fluorescence polarization Figure 3
Competitive nucleotide binding assay using fluorescence polarization. Serial dilutions of cAMP or 8-[ϕ-575]-cAMP in 
the presence of 1 nM 8-Fluo-cAMP were prepared. 2.5 nM R subunit was added and fluorescence polarization was determined 
at Ex485 nm/Em535 nm. EC50 values for cAMP and 8-[ϕ-575]-cAMP binding to the R subunit isoforms were deducted from the 
corresponding titration curves. Each data point represents the mean +/- S.E.M. from at least triplicate measurements.
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8-[ϕ-575]-cAMP is a potent PKA activator in vitro Figure 4
8-[ϕ-575]-cAMP is a potent PKA activator in vitro. For determination of apparent activation constants, purified recom-
binant R subunits were allowed to form holoenzyme complexes with PKA-Cα (20 nM) as detailed in the methods section. 
Activation assays were performed by increasing (0.3 nM-10 μM) cAMP. To obtain apparent activation constants (Kact), the nor-
malized activity of PKA-Cα was plotted against the logarithm of the cAMP ( ) and 8-[ϕ-575]-cAMP ( ) concentration and fitted 
according to a sigmoid dose-response model (Graphpad Prism, variable slope). Each data point represents the mean ± S.D. of 
two measurements. Experiments were repeated two to three times with similar results.
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which in turn is ligand-dependent, this probe is used to
estimate the intracellular level of cAMP or -analogs.
The cells were treated with 500 μM 8-[ϕ-575]-cAMP for
one hour and, during this period, FRET ratio increased lin-
early (Fig. 7a–d). On the basis of the cAMP dose-FRET
response curve [39], we estimate that about 7 μM 8-[ϕ-
575]-cAMP is available to the intracellular fluorescent
indicator. The same experiments were performed using
Sp-5,6-DCl-cBIMPS, a highly membrane permeable cAMP
analog [36]. In this case, after 40 minutes of treatment, the
fluorescent probe was almost completely saturated (Fig.
7e–h), indicating that Sp-5,6-DCl-cBIMPS crosses the
plasma membrane more efficiently compared to 8-[ϕ-
575]-cAMP, in contrast to the retention based lipophilic-
ity measurements on HPLC, where the analogs behaved
more similarly. We can not exclude, however, that the
Epac- based FRET sensor used for the measurements pref-
erentially binds Sp-5,6-DCl-cBIMPS.
As the reduced intracellular availability of 8-[ϕ-575]-
cAMP could also be due to intracellular PDE-mediated
degradation, we tested stability of the compound towards
a cAMP-specific PDE isoform (PDE4D5) in vitro using a
coupled spectrophotometric activity assay [40]. No degra-
dation of 8-[ϕ-575]-cAMP was detected during the 15
minutes of assay duration (data not shown). The specific
activity of the enzyme was 0.6 U/mg for cAMP. It has been
demonstrated before, that 8-modified cAMP analogs pos-
sess considerably high resistance towards PDE degrada-
tion [41]. Absolutely stable analogs would arise from
conjugating the Pharos fluorophore to phosphorothioate-
modified structures such as Rp- or Sp-cAMPS (Rp- or Sp-
diastereomer of adenosine 3'-5'-monophosphorothio-
rate).
We next tested if 8-[ϕ-575]-cAMP can activate the PKA
holoenzyme in living COS-7 cells using a recently estab-
lished bioluminescence resonance energy transfer (BRET)
based reporter for PKA-IIα, based on transient co-
expressed luciferase-tagged RIIα and (RIIα-RLuc) as the
BRET donor and a GFP-tagged Cα subunit (GFP2-Cα) as
the BRET acceptor. In this assay, a decrease in BRET signal
indicates intracellular dissociation of the PKA holoen-
zyme [42]. As depicted in figure 8a, the cAMP analog effi-
ciently allows the PKA subunits to dissociate. Half-
maximal holoenzyme dissociation was achieved at a con-
centration of about 600 μM analog added to the cells. This
value in the same range as the value for e.g. 8-Br-cAMP
(EC50 = 1.5 mM [42]) but is surpassed by acetoxymethyl
esters of cyclic nucleotides, that activate PKA in the low
μM range determined by BRET [7] as well as in physiolog-
ical assays [43]. Finally, we performed a bystander BRET
test [44], where COS-7 cells were transfected with a con-
stant amount of donor-expression plasmid (RIIα-RLuc,
0.5 μg) and with increasing amounts of acceptor-expres-
sion plasmid (GFP2-Cα, 0–2 μg). The cells were incubated
with 600 μM 8-[ϕ-575]-cAMP for 30 minutes prior to the
BRET ratio determination, or mock treated. Figure 8b
depicts the normalized BRET-values of two experiments
each performed with n = 6 wells per incubation. When no
BRET acceptor is expressed in the cells, we observed the
background BRET value, and the incubation with 8-[ϕ-
575]-cAMP has no effect. With increasing amounts of
acceptor DNA, the BRET values rises and reaches an
asymptote at the 1:1 molar ratio at 0.5 μg donor and
acceptor coding DNA each, as expected from a 1:1 interac-
tion of PKA subunits in the holoenzyme. Thereafter the
BRET value does not increase further, indicating a specific
interaction, which can be prohibited to about 50% by
incubation with 600 μM 8-[ϕ-575]-cAMP, as determined
previously (see figure 8a and 8b).
Conclusion
We can conclude that 8-[ϕ-575]-cAMP with its modern,
red-shifted fluorophore is a useful, stable tool for in vitro
and  in vivo investigation of cAMP binding proteins. It
spontaneously enters eukaryotic cells and can be seques-
tered to PKA regulatory subunits. However, undesired par-
tial accumulation in the cell could not be entirely
excluded in this study. It efficiently binds to and activates
Visualization of compounds in living cells Figure 5
Visualization of compounds in living cells. Intracellular 
imaging of 8-[ϕ-575]-cAMP (a-b) and of Pharos dye (c-d) in 
HEK293 (a,c) and in CHO (b,d) cells after 1 hour of treat-
ment.BMC Biochemistry 2008, 9:18 http://www.biomedcentral.com/1471-2091/9/18
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PKA-I and -II, and should have great potential for many
cell biological and in vitro applications.
Methods
Materials
All cyclic nucleotides, as well as the free Pharos chromo-
phore were derived from Biolog Life Science Institute
(Bremen, Germany). The solubility of the novel Pharos
compound is approximately 50 mM in water. LogKw data
were determined by a retention-based lipophilicity rank-
ing using a LiChrograph HPLC (Merck-Hitachi, Darm-
stadt, Germany) equipped with a reversed phase YMC RP-
18 phase (250 × 4 mm) running at a flow rate of 1.0 ml/
min. Nucleotides were detected at λ = 280 nm [35]. A. The
purity of cyclic nucleotides was analyzed with an elution
system consisting of 25% acetonitrile and 10 mM triethyl
ammonium formiate at a flow rate of 1.5 ml/min and was
found to be > 99%. No trace of free fluorophore was
detected in 8-[ϕ-575]-cAMP.
Spectral measurements
The Pharos dye was diluted in 20 mM 2-(4-morpholino)-
ethane sulfonic acid (MES) buffer adjusted to pH 6.0, pH
7.0 and pH 7.4, and all samples were degassed by bub-
bling nitrogen through the solution before measuring the
absorption or fluorescence spectra.
For Stokes shift and quantum yield determination,
absorption and fluorescence spectra were recorded in cells
with 1 cm path length using a PerkinElmer Lambda 900
UV-Vis spectrophotometer and a Hitachi F-4500 fluores-
cence spectrophotometer, respectively.
To calculate the relative quantum yield ϕ of the free Pha-
ros dye, the absorption (500 nm to 640 nm) and fluores-
cence (λex = 553 nm, λem ranging from 558 nm to 800 nm)
spectra of several Pharos dye concentrations (640 nM to
64.2 μM) were recorded in A. bidest. The integrated fluo-
rescence intensity (I) was plotted versus the absorbance
(A) at the excitation wavelength. For low concentrations
the dye molecules are not influenced by each other and
thus exhibit a linear behavior concerning absorption and
emission of light. Linear regression yields the slope ΔI/ΔA
that is compared to the corresponding data of a quantum
yield standard by using the equation ϕsa  = (ΔIsa/
ΔAsa)·(ΔAst/ΔIst)·ϕst. As a standard, a solution of quinine
sulfate in 1.0 N sulfuric acid (ϕst = 0.546 with λex = 365
nm) was used [21,22].
For emission and excitation spectra (Kontron SFM25)
with and without purified regulatory subunit of PKA (see
below), 100 nM 8-[ϕ-575]-cAMP was measured with and
without fourfold molar excess of regulatory subunit in 20 
Co-localization of 8-[ϕ-575]-cAMP and GFP-tagged R subunits Figure 6
Co-localization of 8-[ϕ-575]-cAMP and GFP-tagged R subunits. COS-7 cells were transiently transfected with GFP-
hRIα (a-c) and GFP-hRIIα (d-f), incubated with 500 μM 8-[ϕ-575]-cAMP for 30 minutes. Cells were fixed and fluorescence was 
imaged using confocal microscopy: (a,c) green fluorescence of GFP (b,e), red fluorescence of 8-[ϕ-575]-cAMP, (c,f) merged 
images. The scale bar indicates 10 μm.
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8-[ϕ-575]-cAMP activates intracellular PKA Figure 8
8-[ϕ-575]-cAMP activates intracellular PKA. (a) For standard BRET experiments, COS-7-cells were co-transfected with 
the PKA type II sensor construct or negative control plasmids (bg) as indicated and grown for 48 hours. Cells were treated 
with the indicated amount of 8-[ϕ-575]-cAMP for 30 minutes, or mock treated (D-PBS). BRET signals were obtained after 
addition of the luciferase substrate DeepBlueC™ and detection of luciferase and fluorescence light emission using a multi-label 
reader. Shown is a representative experiment, repeated three times; data are mean ± S.E.M., performed with n = 6 replicates. 
(b) A BRET titration experiment was performed as described in the methods section. Briefly, cells were co-transfected with a 
constant amount of BRET donor (hRIIα-Rluc) and an increasing amount of acceptor DNA (GFP2-hCα) as indicated. Before 
BRET read-out, cells were incubated with 0.6 mM 8-[ϕ-575]-cAMP as described above. The BRET values of two independent 
experiments, each performed with n = 6 replicates, were background subtracted, normalized and plotted as mean ± S.E.M.
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Uptake of 8-[ϕ-575]-cAMP in intact cells Figure 7
Uptake of 8-[ϕ-575]-cAMP in intact cells. Kinetics of 8-[ϕ-575]-cAMP (a-d) and of Sp-5,6-DCI-cBIMPS (e-h) uptake in liv-
ing cells. HEK293 cells were transfected for transient expression of the H30 indicator of cAMP and treated with 100 μM IBMX 
to inhibit phosphodiesterases. The ratio between the background subtracted emission intensities at 480 nm and 545 nm is plot-
ted as a function of time. The vertical bars indicate the administrations of either 500 μM 8-[ϕ-575]-cAMP (a-d) or Sp-5,6-DCl-
cBIMPS (e-h) and of 25 μM Forskolin, which activates adenylyl cyclase and saturates the FRET-based probe. The insets show 
the yellow fluorescent protein fluorescence at the beginning of the experiments and the regions of interest where FRET ratios 
are calculated.
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mM MOPS, 150 mM NaCl, 1 mM β-mercaptoethanol, pH
(buffer A) at room temperature. The excitation spectra
were detected at λem = 617 nm with λex ranging from 610
nm to 430 nm; emission spectra were measured with λex =
575 nm with λem ranging from 800 nm to 580 nm.
Expression and purification of PKA subunits
For expression of PKA regulatory subunits, one liter of
Luria Broth medium containing 100 μg/ml of ampicillin
was inoculated with E. coli BL21 (DE3) Codon Plus RIL
cells (Stratagene) transformed with human RIα, RIβ, RIIα
(in pRSETB) or rat RIIβ (in pETIIc) and grown at 37°C to
an OD600 nm of 0.8. Recombinant protein expression was
induced by addition of 0.2 M isopropyl-β-D-thiogalacto-
pyranoside (IPTG) and the culture was incubated at 25°C
for additional 17–18 h. The pellets were stored at -20°C.
For purification of RI isoforms (Moll et al., submitted),
cell lysis of protein expressing E. coli cells was performed
two times with a French Pressure Cell (Thermo Electron
Corp., Needham Heights, USA) in lysis buffer (20 mM 3-
(N-morpholino) propane sulfonic acid (MOPS), 100 mM
NaCl, 1 mM β-mercaptoethanol, 2 mM EDTA, 2 mM
EGTA, pH7.0). The lysate was centrifuged at 27 000 ×g for
30 min and 4°C. 1.2 μmol Sp-8-AEA-cAMPS-agarose
(Biolog Life Science Inst.) was used per purification, cor-
responding to 300–450 μl agarose-slurry. The protein
content in 12 ml clarified supernatant was batch bound
by gentle rotation over night by 4°C. The agarose was
washed seven times with 1.25 ml lysis buffer. The protein
elution step was performed with 1.25 ml of 10 mM cGMP
in buffer A by gentle rotation at 4°C for 1 h. The agarose
was rinsed with two additional wash steps (each 825 μl)
with buffer A. Subsequently, the R subunits were sub-
jected to gel filtration (PD10, Amersham Pharmacia Bio-
tech, Freiburg, Germany) into buffer A. To remove all
cGMP, the R subunits were dialyzed excessively against
buffer A.
For purification of RII isoforms (Moll et al., submitted),
cell lysis was performed in buffer consisting 20 mM MES,
pH6.5, 100 mM NaCl, 5 mM EDTA, 5 mM EGTA and 5
mM β-mercaptoethanol with added protease inhibitors
(PI): Leupeptin (0.025 mg/100 ml), TPCK and TLCK
(each 1 mg/100 ml) (buffer B). after centrifugation at 27
000 ×g for 30 min and 4°C, the supernatant was precipi-
tated at 4°C with 50% saturated ammonium sulfate (AS)
for RIIα and 45% AS for RIIβ and centrifuged by 10 000
×g, 15 min 4°C. The AS pellets were re-suspended in
buffer B and protein was batch bound to 1.4 μmol settled
Sp-8-AEA-cAMPS-agarose. The agarose was rinsed twice
with 20 mM MOPS, pH7.0, 1 M NaCl, 5 mM β-mercap-
toethanol and then two times with 10 ml buffer B. Subse-
quently, two elution steps were carried out with 25 mM
cGMP in buffer B. RII subunits were subjected to gel filtra-
tion into 20 mM MES, pH 6.5,150 mM NaCl, 2 mM
EDTA, 2 mM EGTA, 1 mM β-mercaptoethanol.
Murine Cα subunit (in pRSETB) was expressed in E. coli
BL21 (DE3) (Stratagene) and purified as published previ-
ously [45,46]. Protein expression and purification was fol-
lowed by SDS-polyacrylamid gel electrophoresis [47].
Typically, the recombinant proteins were purified to 95%
homogeneity or higher.
Fluorescence Polarization (FP)
The fluorescence polarization displacement assay was per-
formed as described before[7]. Increasing concentrations
of cAMP or 8-[ϕ-575]-cAMP were mixed with 1 nM 8-
Fluo-cAMP before adding 2.5 nM regulatory subunit RIα,
RIIα, RIIβ. Fluorescence polarization was measured after 5
minutes of incubation at room temperature.
Determination of activation constants
PKA activity was assayed by the coupled spectrophoto-
metric assay first described by Cook et al. [26] using 260
μM Kemptide (LRRASLG) as the substrate. Holoenzyme
formation was carried out for 3 minutes at room temper-
ature with 20 nM murine PKA-Cα subunit and an about
1.2 fold molar excess cAMP-free RIα, RIIα, or RIIβ subunit
in assay mixture (10 mM MgCl2, 100 μM ATP, 100 mM
MOPS, 1 mM PEP, LDH, pyruvate kinase, NADH, 5 mM
β-mercaptoethanol, pH 7.0). Apparent activation con-
stants (Kact, EC50) were determined by adding increasing
amounts of cAMP or 8-[ϕ-575]-cAMP (0.3 nM to 10 μM).
BRET assay
COS-7 cells were used for BRET experiments. They were
routinely passaged and seeded in opaque 96-well micro-
plates (CulturPlate™-96, PerkinElmer) 24 hours prior to
co-transfection with the previously described PKA-IIα sen-
sor, comprised of RIIα-RLuc (donor) and GFP2-Cα
(acceptor) [42]. Two days following transfection with 0.5
μg donor and acceptor DNA, respectively, cells were
rinsed with glucose-supplemented Dulbecco's PBS (D-
PBS, Invitrogen), and subsequently incubated with 8-[ϕ-
575]-cAMP (0.01–6 mM final concentration in D-PBS,
prepared from a 20 mM stock solution), or mock treated
for 30 minutes at room temperature. For the BRET read-
out, the luciferase substrate DeepBlueC™ (PerkinElmer)
was added at a final concentration of 5 μM in a total vol-
ume of 50 μl D-PBS. Light output was detected consecu-
tively using a Fusion™ α-FP microplate reader
(PerkinElmer, read time 1s, gain 25) equipped with
appropriate filters for the donor (RLuc; λ = 410 nm ± 80
nm) and for the acceptor fluorophore (GFP2; λ = 515 nm
± 30 nm) emission. Emission values obtained with
untransfected (n.t.) cells were routinely subtracted, and
BRET signals were calculated as follows: (emission(515nm)
– n.t. cells(515nm))/(emission(410nm)  – n.t. cells(410nm)).BMC Biochemistry 2008, 9:18 http://www.biomedcentral.com/1471-2091/9/18
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Control measurements with cells expressing RLuc and
GFP proteins without a fusion partner yield the back-
ground BRET signal. A BRET titration (bystander BRET
test) was performed by co-transfection of COS-7 cells with
a constant donor-expression plasmid (0.5 μg) with an
increasing amount of acceptor-expression plasmid (0–2
μg). The cells were treated as described above. Prior to the
BRET read-out, cells were incubated with or without 0.6
mM 8-[ϕ-575]-cAMP for 30 minutes.
Uptake of 8-[ϕ-575]-cAMP in living cells
HEK293 and CHO cells were grown in the Dulbecco's
modified Eagle medium (DMEM, Invitrogen) and F12
nutrient mixture (HAM, Invitrogen) mediums, respec-
tively, containing 10% FBS and supplemented with 2 mM
L-glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin (all: Sigma-Aldrich), in a 37°C humidified atmos-
phere containing 5% CO2. These cell lines are routinely
used in our laboratory for FRET experiments using various
sensors and they have been thoroughly characterized for
fluorescent sensor expression levels.
For transient expression of the H30 sensor, cells were
seeded onto 24-mm diameter round glass coverslips, and
transfections were performed at 50–70% confluence with
FuGENE-6 transfection reagent (Roche). Imaging experi-
ments were performed after about 24 h. Cells were main-
tained in Hepes-buffered Ringer-modified solution,
containing 125 mM NaCl, 5 mM KCl, 1 mM Na3PO4, 1
mM MgS04, 5.5 mM glucose, 1 mM CaCl2, and 20 mM
Hepes, pH 7.4, at room temperature and treated with 100
μM 3-Isobutyl-1-methylxanthine (IBMX, Sigma-Aldrich)
10 minutes before the experiments. Cells were imaged on
an inverted microscope (IX50; Olympus) with a 60× oil
immersion objective (Olympus). The microscope was
equipped with a monochromator (Polychrome IV; TILL
Photonics) and a beam-splitter optical device (Multispec
Microimager; Optical Insights). FRET variations were
measured as changes of the ratio between the back-
ground-subtracted fluorescence emission intensities at
480 nm and 545 nm, on excitation at 430 nm. Forskolin
(25 μM, Sigma-Aldrich) was added to saturate the FRET
probe and to determine the maximal FRET response.
For the imaging of the intracellular distribution of 8-[ϕ-
575]-cAMP and the Pharos dye, cells were grown and
seeded as above. Before the image acquisitions, cells were
treated with 100 μM IBMX and either 500 μM 8-[ϕ-575]-
cAMP or the Pharos dye for 1 hour. Cells were then
washed with the Hepes-buffered Ringer-modified solu-
tion described above and imaged on a confocal micro-
scope (Leica) with a 20× oil immersion objective (Leica).
Images were obtained by collecting the emission light
from 600 nm to 640 nm, on excitation at 514 nm.
Intracellular co-localization of 8-[ϕ-575]-cAMP and GFP-
hRIα or GFP-hRIIα was examined in COS-7 cells after two
days transient expression of the GFP-tagged R subunits
[42]. Cloning of the R subunits into the expression vector
hpGFP2-N2  (PerkinElmer) was performed as described
previously [48]. The cells were incubated for 30 minutes
at 37°C with 500 μM 8-[ϕ-575]-cAMP in D-PBS, rinsed
tree times with D-PBS, followed by a standard fixation
procedure [42]. Cellular imaging was performed on a con-
focal microscope (Leica) with a Plan apo 100× oil immer-
sion objective (Leica).
Statistical procedures
Measurement and statistical evaluation of FP, kinase activ-
ity and BRET assays was carried out using GraphPad Prism
software version 4 (GraphPad Software).
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phorothioate, Sp-isomer; 8-pCPT-2'-O-Me-cAMP: 8-(4-
chlorophenylthio)-2'-O-methyladenosine -3',5'-cyclic
monophosphate; 8-Br-cAMP: 8-Bromoadenosine -3',5'-
cyclic monophosphate; Sp-8-AEA-cAMPS-agarose: 8-(2-
aminoethylamino)adenosine -3',5'-cyclic monophospho-
rothioate, Sp- isomer, immobilized to agarose; MOPS: 3-
(N-morpholino) propane sulfonic acid; MES: 2-(4-mor-
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